Brequinar

Brequinar

Clinical data
Trade names	Brequinar
Identifiers
IUPAC name 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid
CAS Number	96187-53-0
PubChem CID	57030
DrugBank	DB03523
ChemSpider	51422
UNII	5XL19F49H6
KEGG	D03154
ChEBI	CHEBI:177387
ChEMBL	ChEMBL38434
CompTox Dashboard (EPA)	DTXSID00242165
Chemical and physical data
Formula	C23H15F2NO2
Molar mass	375.4 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O
InChI InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28) Key:PHEZJEYUWHETKO-UHFFFAOYSA-N

Brequinar (DuP-785) is a drug that acts as a potent and selective inhibitor of the enzyme dihydroorotate dehydrogenase. It blocks synthesis of pyrimidine based nucleotides in the body and so inhibits cell growth. Brequinar was invented by DuPont Pharmaceuticals in the 1980s. In 2001, Bristol-Myers Squibb acquired DuPont, and in 2017, Clear Creek Bio acquired the rights to brequinar from BMS.

Brequinar has been investigated as an immunosuppressant for preventing rejection after organ transplant and also as an anti-cancer drug, but was not accepted for medical use in either application largely due to its narrow therapeutic dose range and severe side effects when dosed inappropriately. It has been researched both as part of a potential combination therapy for some cancers, or alternatively as an antiparasitic, or antiviral drug. Clear Creek Bio is currently developing brequinar as a potential treatment for COVID-19.

Inhibition of dihydroorotate dehydrogenase activity by brequinar may represent an efficient approach to the elimination of undifferentiated cells for safe PSC‐derived differentiated cells based therapies.

See also

• Leflunomide - Clinically used DHODH inhibitor
• Methotrexate - the most widely used pyrimidine synthesis inhibitor